
Pharmaceutical Industry Representative Comment Process at AHCCCS Pharmacy & Therapeutics Committee Meetings

- A. Pharmaceutical representatives presenting clinical information to the AHCCCS Pharmacy & Therapeutics Committee (P&T) must register to present at the meeting, no later than one month prior to the P & T Meeting. Pharmaceutical representative may email the AHCCCS pharmacy office at:

AHCCCSPharmacyDept@azahcccs.gov

- B. Pharmaceutical representatives shall submit clinical information to be presented at the meeting to the AHCCCS Pharmacy Department for review prior to the meeting at the above email address.
- C. All clinical information submitted must include a one-page cover sheet that summarizes the key points and directs the Committee members to the key areas of the submitted information for consideration. Page number, paragraphs and line numbers should be cited.
- D. Presentation content by commenters is limited to drugs relevant to the drug classes specified in the meeting agenda.
- E. Information submitted is restricted to new studies released since the last review, and is limited to randomized double-blinded active control studies. Studies must have been published or accepted for publication in a peer-reviewed journal.
- F. Online publications, poster presentations and placebo controlled, observational, open-label and non-randomized studies are not accepted for consideration.
- G. Product monographs and dossiers, P&T Committee briefs, extensive bibliographies, or similar inclusions will not be considered.
- H. Persons/entities who present must sign in at least ten (10) minutes prior to the start of the P & T Committee meeting; otherwise the person/entity may not be permitted to present comments.
- J. Presentations:
- (1) The P & T Chair or designee will recognize the speakers in alphabetical order of the medications listed in the therapeutic class being reviewed.
 - (2) Speakers may only provide comments verbally; no visual or audio aids may be used.
 - (3) Written documents or handouts shall only be provided to Committee members at the meeting.
 - (4) Speakers are limited to comments and/or presentations that do not exceed three (3) minutes per drug, per class, per manufacturer.
- K. Questions or comments from the P&T Committee will not be entertained unless the P & T Committee Chair person grants approval for questions and/or comments from the Committee members. The P & T Committee Chair may suspend or eliminate the comment process for reasons including, but not limited to, speaker noncompliance with the comment process, time constraints, and/or the quality of information presented.